Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#1999 Study of Cell Cycle Protein Expression Pattern in Bronchial Carcinoids: A New Potential Target for Medical Therapy?

Introduction: Bronchial Carcinoids (BCs) are rare neuroendocrine neoplasms arising from respiratory epithelium. The only effective treatment option is surgery, but its efficacy is frequently limited by metastatic spread. Everolimus prolongs progression free survival but patients may develop resistance. Previous studies demonstrated that Everolimus reduces viability of NCI-H720 cells (Atypical Carcinoid) but not of NCI-H727 cells (Typical Carcinoid). Everolimus decreases Ciclyn D1 protein levels in both cell lines but NCI-H727 cells survive, indicating a derangement in cell cycle control.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Bresciani G, Riva E, Ambrosio M, Zatelli M,

Keywords: bronchial carcinoids, cell cycle, cyclins, cdks, target therapy, everolimus, dinaciclib, palbociclib,

#1877 TSC22D1 Expression and Association with Clinic-Pathological Features in Bronchial Carcinoids

Introduction: Bronchial carcinoids (BC), typical (TC) or atypical (AC), are rare neoplasms arising from neuroendocrine cells spread in the respiratory epithelium Microarray data analysis obtained comparing a pool of TC with a pool of AC samples showed TSC22D1 down-regulation in AC samples. The role of TSC22D1 in neuroendocrine tumors is unknown.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Zatelli M

Authors: Falletta S, Gentilin E, Riva E, Bresciani G, Degli E,

Keywords: TSC22D1, bronchial carcinoids, aggressiviness,

#1494 CDK-Inhibitors as New Therapeutic Treatment for Human Bronchial Carcinoids

Introduction: Bronchial Carcinoids (BC) are still orphan of medical therapy. We previously demonstrated that 70% of primary BC cultures are sensitive to Everolimus (E), an mTOR inhibitor, while 30% are not. We also observed that in 2 human BC cell lines, the NCI-H720 (sensitive to E) and NCI-H727 (resistant to E), mTOR resistance may be linked to a differential cell cycle protein expression (CyclinD1/E, CDK2/4, p27kip1/p27kip1phospho-Ser10), which is higher in BC resistant to E as compared to sensitive ones, suggesting an impaired p27 function

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: BENFINI K

Authors: Benfini K, Gentilin E, Riva E, Di Pasquale C, Falletta S,

Keywords: Bronchial Carcinoid, Medical Therapy, mTOR Resistance, CDK inhibitors,

#1337 O6-Methylguanine DNA Methyltransferase (MGMT) Deficiency and Response to Aranoza-Based Therapy in Patients with Neuroendocrine Tumors

Introduction: Aranoza (3-α-L-arabinopyranosyl-1-methyl-nitrosourea) – nitrosourea derivative, as STZ. O6-methylguanine DNA methyltransferase (MGMT) is an enzyme implicated in chemotherapy resistance to alkylating agents and its low levels are associated with sensitivity to them.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Polozkova S, Stepanova E, Delektorskaya V, Kozlov N, Gorbunova V,

Keywords: aranoza, MGMT, chemotherapy, NETs,

#1301 Role of TSC22D1 (TGFβ-Stimulated Clone 22 Domain Family Member 1) in Bronchial Carcinoids

Introduction: Neuroendocrine tumors (NETs) include bronchial carcinoids, either typical (TC) or atypical (AC). Tsc22d1 encodes for a member of TSC22 domain family of leucine zipper transcription factors; the protein (TSC22D1) is stimulated by TGFβ. Microarray data analysis obtained comparing a pool of TC tissue specimens with a pool of AC tissue specimens shows TSC22D1 down-regulation in AC samples. These data were confirmed by real time PCR and Western blot in vitro models of TC (NCI-H727 cells) and AC (NCI-H720 cells)

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Falletta S, Gagliano T, Di Pasquale C, Benfini K, Riva E,

Keywords: TSC22D1, bronchial carcinoid, TGFβ,